ClinicalTrials.gg

Program

NP-G2-044

Also written as “NP-G2-044 Monotherapy” and “NP-G2-044 Combination therapy”.

Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms, led by Novita Pharmaceuticals.

Furthest: phase 3, since Jul 31, 20253 company-led studies, 1 open or runningNext primary completion: Oct 25, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novita Pharmaceuticals31 open or runningphase 3since Jul 31, 2025Jun 23, 2017Oct 25, 2028phase 3 · NCT07109414

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 23, 2017First study: phase 1 study in Breast NeoplasmsFirst studyNCT03199586 · 23 enrolled · United States
  2. Jul 30, 2021Phase 2 study in Advanced or Metastatic Solid Tumor MalignanciesNCT05023486 · 121 enrolled · United States
  3. Jul 31, 2025Phase 3 study in Ovarian NeoplasmsNCT07109414 · 380 enrolled · United States

Ahead

  1. Oct 25, 2028Primary completion: phase 3 study in Ovarian NeoplasmsNCT07109414

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07109414Ovarian Neoplasms · United States3Active, not recruitingOct 25, 2028380
NCT05023486Advanced or Metastatic Solid Tumor Malignancies · United States2CompletedJun 30, 2026121
NCT03199586Breast Neoplasms · United States1CompletedMay 7, 202023

How it is read

Names in the registry

  • “NP-G2-044”, 2 entries
  • “NP-G2-044 Monotherapy”, 1 entry
  • “NP-G2-044 Combination therapy”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.